Association Between Cyclin-Dependent Kinase 4/6 Inhibitors and Nephrotoxicity in Patients with Breast Cancer: A Systematic Review and Meta-analysis

This study conducted a meta-analysis of 17 randomized controlled trials involving 19,638 patients to assess the risk of nephrotoxicity associated with cyclin-dependent kinase (CDK) 4/6 inhibitors in breast cancer treatment. The analysis found a significant increase in all-grade nephrotoxic adverse events (AEs), including elevated blood creatinine, acute kidney injury, and renal impairment (RR = 3.12, 95% CI [2.11, 4.63]). The incidence of grade 3 or higher nephrotoxicity was also notably higher in treated patients (RR = 3.12, 95% CI [1.74, 5.58]). Subgroup analyses indicated differential risks across the four CDK4/6 inhibitors. These results underscore the importance of clinicians closely monitoring renal function in patients receiving CDK4/6 inhibitors.

本研究对17项随机对照试验进行了荟萃分析，涉及19,638名患者，旨在评估乳腺癌治疗中 Cyclin-dependent kinase (CDK) 4/6 抑制剂相关肾毒性的风险。分析结果显示，所有级别的肾毒性不良事件（包括血肌酐升高、急性肾损伤和肾功能损害）的发生率显著增加（相对风险 RR = 3.12，95% 置信区间 [2.11, 4.63]）。接受治疗的患者的3级或以上肾毒性发生率也明显升高（相对风险 RR = 3.12，95% 置信区间 [1.74, 5.58]）。亚组分析表明，四种 CDK4/6 抑制剂之间存在不同的风险。这些结果强调了临床医生在 CDK4/6 抑制剂治疗患者中密切监测肾功能的重要性。